Keywords
How to Cite
Abstract
Aim: study of the predictive value of determining ctDNA during treatment with osimertinib in patients with NSCLC with EGFR mutation. Methods: The study included patients with metastatic EG-FR-associated NSCLC, in whom, with progression against the background of 1st - 2nd generation TKIs, the T790M mutation was detected. Patients received osimertinib therapy 80 mg/ day, daily, until progression. Before treatment, and then every 2 months, whole blood was taken to conduct a qualitative assessment of ctDNA in dynamics by the RT-PCR method. Results: From 2016 to 2019 in St. Petersburg Clinical Scientific and Practical Center of Specialized Types of Medical Care (Oncology), 22 patients were identified T790M associated progression of EGFR NSCLC. 81.9% (18/22) are women, 18.1% (4/22) are men. The average age is 61.2 years (50-75). 1/22 had smoking experience for more than 30 years. The molecular genetic profile in 16 is represented by ex19del, 5 L858R, 1 -a combination of rare mutations G719S+S768I. The effect of therapy was evaluated in 20/22 patients. PR and SD were registered in 9/20 (45%) and 10/20 (50%) patients, respectively. Median PFS - 16.7 months (cI 95%, 11,4-22,0). In 12/22 patients was observed the disappearance of ctDNA T790M after 2 months of osimertinib therapy. PFS is 18,9 months (95% CI, 14,8-19,7), in patients with no mutation detected in the second month of treatment compared with the group of patients in which the ctDNA was determined (PFS 8.0 months) (CI 95%, 4,2-11,8) (p=0.015). Correlation analysis did not reveal any clinical factors associated with the disappearance of ctDNA. Conclusions: The disappearance of ctDNA in plasma after 2 months of treatment with osimertinib is associated with an increase in PFS and can be considered as a predictive marker in patients with metastatic NSCLC EGFR T790M.
References
Goto K., Ichinose Y., Ohe Y. et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPAss, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer // J. Thorac. Oncol. - 2012. - Vol. 7(1). - P. 115-121.
Decoster L., Giron P., Mignon S., De Grève J. The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations // Translational Lung Cancer Research. - 2018. - Vol. 7(S2). - S134-S137. - DOI: 10.21037/tlcr.2018.03.08
Lee C.K., Davies L., Wu Y-L. et al. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival // JNCI: Journal of the National Cancer Institute. - 2017. - Vol. 109(6). - DOI: 10.1093/jnci/djw279
Yu H.A., Arcila M.E., Rekhtman N. et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers // Clinical Cancer Research. - 2013. - Vol. 19(8). - P. 2240-2247. DOI: 10.1158/1078-0432.ccr-12-2246
Cross D.A., Ashton S.E., Ghiorghiu S. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer // Cancer Discovery. - 2014. - Vol. 4. - P. 1046-1061.
Ward R.A., Anderton M.J., Ashton S. et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) // J. Med. Chem. - 2013. - Vol. 56. - P. 7025-7048.
Yang JC-H., Ahn M-J., Kim D-W. et al. Osimertinib in pretreated T790Mpositive advanced non-small-cell lung cancer: AURA Study Phase II Extension Component // J. Clin Oncol. - 2017. - Vol. 35(12). - P. 1288-1296.
Jnne P.A., Yang J.C.-H., Kim D.-W. et al. AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer // New England Journal of Medicine. - 2015. - Vol. 372(18). - P. 1689-1699. - DOI: 10.1056/nejmoa1411817
Mok T.S., Wu Y-L., Ahn M.-J. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer // N. Engl. J. Med. - 2017. - Vol. 376. - P 629-640.
Novello S., Barlesi F, Califano R. et al. Metastatic nonsmall-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. - 2016. - Vol. 27(suppl_5). - v1-v27. - DOI: 10.1093/annonc/mdw326
Oxnard G.R., Thress K.S., Alden R.S. et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer // J Clin Oncol. - 2016. - Vol. 34(28). - P. 3375-3382.
Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) // European Journal of Cancer. - 2009. - Vol. 45(2). - P. 228-247. - DOI: 10.1016/j.ejca.2008.10.026
Hanfstein B., Shlyakhto V., Lauseker M. et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid Leukemia (CML) patients in chronic phase on treatment with imatinib // Leukemia. - 2014. - Vol. 28(10). - P. 1988-1992. - DOI: 10.1038/leu.2014.153
Pines A. Acute mountain sickness // The Lance. - 1977. - Vol. 309(8006). - P. 316. - DOI: 10.1016/s0140-6736(77)91875-x
Zheng P., Zeng B., Zhou C. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism // Molecular Psychiatry. - 2016. - Vol. 21(6). - P. 786-796. - DOI: 10.1038/mp.2016.4435136
Mok T et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy // Clin. Cancer Res. - 2015. - Vol. 21. - P. 3196-3203.
Chmielecki J., Foo J., Oxnard G.R. et al. Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling // Science Translational Medicine. - 2011. - Vol. 3(90). - 90ra59-90ra59. - DOI: 10.1126/scitranslmed.3002356
Provencio M., Torrente M., Calvo V. et al. Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients // Oncotarget. - 2017. - Vol. 9(1). - DOI: 10.18632/oncotarget.22470
Hata A., Katakami N., Yoshioka H. et al. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI // Journal of Thoracic Oncology. - 2015. - Vol. 10(11). - P. 1553-1559. - DOI: 10.1097/jto.0000000000000647
Sundaresan T.K., Sequist L.V., Heymach J.V. et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses // Clin Cancer Res. - 2016. - Vol. 22(5). - P. 1103-1110.
Zheng D., Ye X., Zhang M.Z. et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance // Scientific Reports. - 2016. - Vol. 6(1). - DOI: 10.1038/srep20913
Provencio M., Torrente M., Calvo V. Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients // Oncotarget. - 2017. - Vol. 9(1). - DOI: 10.18632/oncotarget.22470
Mok T.S., Wu Y-L. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer // N. Engl. J. Med. - 2017. - Vol. 376. - P. 629-640. - DOI: 10.1056/NEJMoa161267
Nguyen K.-S.H., Kobayashi S., Costa D.B. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway // Clinical Lung Cancer. -2009. - Vol. 10(4). - P. 281-289. - DOI: 10.3816/clc.2009.n.039
Hochmair M.J., Morabito A., Hao D. et al. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study // Future Oncology. - 2018. - Vol. 14 (27). - DOI: 10.2217/fon-2018-0711
Hochmair M., Holzer S., Burghuber O.C. Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases // AntiCancer Drugs. - 2016. - Vol. 27(9). - P. 914-915. - DOI: 10.1097/cad.0000000000000410
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020